Proportional upregulation of CD97 isoforms in glioblastoma and glioblastoma-derived brain tumor initiating cells

Michael Safaee, Shayan Fakurnejad, Orin Bloch, Aaron J. Clark, Michael E. Ivan, Matthew Z. Sun, Taemin Oh, Joanna J. Phillips, Andrew T. Parsa

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

CD97 is a novel glioma antigen that confers an invasive phenotype and poor survival in patients with glioblastoma (GBM), the most aggressive primary malignant brain tumor. The short isoform of CD97, known as EGF(1,2,5), has been shown to promote invasion and metastasis, but its role in gliomas and GBM-derived brain tumor initiating cells (BTICs) has not been studied. We sought to characterize CD97 expression among gliomas and identify the specific isoforms expressed. The short isoform of CD97 was identified in GBM and GBMderived BTICs, but not low grade or anaplastic astrocytomas. All samples expressing the EGF(1,2,5) isoform were also found to express the EGF(1,2,3,5) isoform. These isoforms are believed to possess similar ligand binding patterns and interact with chondroitin sulfate, a component of the extracellular matrix, and the integrin α5β1. Using data acquired from the Cancer Genome Atlas (TCGA), we show that CD97 is upregulated among the classical and mesenchymal subtypes of GBM and significantly decreased among IDH1 mutant GBMs. Given its proven roles in tumor invasion, expression among aggressive genetic subtypes of GBM, and association with overall survival, CD97 is an attractive therapeutic target for patients with GBM.

Original languageEnglish (US)
Article numbere0111532
JournalPloS one
Volume10
Issue number2
DOIs
StatePublished - Feb 25 2015
Externally publishedYes

Fingerprint

Neoplastic Stem Cells
Glioblastoma
Brain Neoplasms
Tumors
Brain
Protein Isoforms
Up-Regulation
brain
neoplasms
Epidermal Growth Factor
Glioma
chondroitin sulfate
integrins
extracellular matrix
metastasis
antigens
phenotype
mutants
therapeutics
genome

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Proportional upregulation of CD97 isoforms in glioblastoma and glioblastoma-derived brain tumor initiating cells. / Safaee, Michael; Fakurnejad, Shayan; Bloch, Orin; Clark, Aaron J.; Ivan, Michael E.; Sun, Matthew Z.; Oh, Taemin; Phillips, Joanna J.; Parsa, Andrew T.

In: PloS one, Vol. 10, No. 2, e0111532, 25.02.2015.

Research output: Contribution to journalArticle

Safaee, M, Fakurnejad, S, Bloch, O, Clark, AJ, Ivan, ME, Sun, MZ, Oh, T, Phillips, JJ & Parsa, AT 2015, 'Proportional upregulation of CD97 isoforms in glioblastoma and glioblastoma-derived brain tumor initiating cells', PloS one, vol. 10, no. 2, e0111532. https://doi.org/10.1371/journal.pone.0111532
Safaee, Michael ; Fakurnejad, Shayan ; Bloch, Orin ; Clark, Aaron J. ; Ivan, Michael E. ; Sun, Matthew Z. ; Oh, Taemin ; Phillips, Joanna J. ; Parsa, Andrew T. / Proportional upregulation of CD97 isoforms in glioblastoma and glioblastoma-derived brain tumor initiating cells. In: PloS one. 2015 ; Vol. 10, No. 2.
@article{a21df2cc2e0d4fb894a13b0f37ab379e,
title = "Proportional upregulation of CD97 isoforms in glioblastoma and glioblastoma-derived brain tumor initiating cells",
abstract = "CD97 is a novel glioma antigen that confers an invasive phenotype and poor survival in patients with glioblastoma (GBM), the most aggressive primary malignant brain tumor. The short isoform of CD97, known as EGF(1,2,5), has been shown to promote invasion and metastasis, but its role in gliomas and GBM-derived brain tumor initiating cells (BTICs) has not been studied. We sought to characterize CD97 expression among gliomas and identify the specific isoforms expressed. The short isoform of CD97 was identified in GBM and GBMderived BTICs, but not low grade or anaplastic astrocytomas. All samples expressing the EGF(1,2,5) isoform were also found to express the EGF(1,2,3,5) isoform. These isoforms are believed to possess similar ligand binding patterns and interact with chondroitin sulfate, a component of the extracellular matrix, and the integrin α5β1. Using data acquired from the Cancer Genome Atlas (TCGA), we show that CD97 is upregulated among the classical and mesenchymal subtypes of GBM and significantly decreased among IDH1 mutant GBMs. Given its proven roles in tumor invasion, expression among aggressive genetic subtypes of GBM, and association with overall survival, CD97 is an attractive therapeutic target for patients with GBM.",
author = "Michael Safaee and Shayan Fakurnejad and Orin Bloch and Clark, {Aaron J.} and Ivan, {Michael E.} and Sun, {Matthew Z.} and Taemin Oh and Phillips, {Joanna J.} and Parsa, {Andrew T.}",
year = "2015",
month = "2",
day = "25",
doi = "10.1371/journal.pone.0111532",
language = "English (US)",
volume = "10",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "2",

}

TY - JOUR

T1 - Proportional upregulation of CD97 isoforms in glioblastoma and glioblastoma-derived brain tumor initiating cells

AU - Safaee, Michael

AU - Fakurnejad, Shayan

AU - Bloch, Orin

AU - Clark, Aaron J.

AU - Ivan, Michael E.

AU - Sun, Matthew Z.

AU - Oh, Taemin

AU - Phillips, Joanna J.

AU - Parsa, Andrew T.

PY - 2015/2/25

Y1 - 2015/2/25

N2 - CD97 is a novel glioma antigen that confers an invasive phenotype and poor survival in patients with glioblastoma (GBM), the most aggressive primary malignant brain tumor. The short isoform of CD97, known as EGF(1,2,5), has been shown to promote invasion and metastasis, but its role in gliomas and GBM-derived brain tumor initiating cells (BTICs) has not been studied. We sought to characterize CD97 expression among gliomas and identify the specific isoforms expressed. The short isoform of CD97 was identified in GBM and GBMderived BTICs, but not low grade or anaplastic astrocytomas. All samples expressing the EGF(1,2,5) isoform were also found to express the EGF(1,2,3,5) isoform. These isoforms are believed to possess similar ligand binding patterns and interact with chondroitin sulfate, a component of the extracellular matrix, and the integrin α5β1. Using data acquired from the Cancer Genome Atlas (TCGA), we show that CD97 is upregulated among the classical and mesenchymal subtypes of GBM and significantly decreased among IDH1 mutant GBMs. Given its proven roles in tumor invasion, expression among aggressive genetic subtypes of GBM, and association with overall survival, CD97 is an attractive therapeutic target for patients with GBM.

AB - CD97 is a novel glioma antigen that confers an invasive phenotype and poor survival in patients with glioblastoma (GBM), the most aggressive primary malignant brain tumor. The short isoform of CD97, known as EGF(1,2,5), has been shown to promote invasion and metastasis, but its role in gliomas and GBM-derived brain tumor initiating cells (BTICs) has not been studied. We sought to characterize CD97 expression among gliomas and identify the specific isoforms expressed. The short isoform of CD97 was identified in GBM and GBMderived BTICs, but not low grade or anaplastic astrocytomas. All samples expressing the EGF(1,2,5) isoform were also found to express the EGF(1,2,3,5) isoform. These isoforms are believed to possess similar ligand binding patterns and interact with chondroitin sulfate, a component of the extracellular matrix, and the integrin α5β1. Using data acquired from the Cancer Genome Atlas (TCGA), we show that CD97 is upregulated among the classical and mesenchymal subtypes of GBM and significantly decreased among IDH1 mutant GBMs. Given its proven roles in tumor invasion, expression among aggressive genetic subtypes of GBM, and association with overall survival, CD97 is an attractive therapeutic target for patients with GBM.

UR - http://www.scopus.com/inward/record.url?scp=84923899594&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923899594&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0111532

DO - 10.1371/journal.pone.0111532

M3 - Article

C2 - 25714433

AN - SCOPUS:84923899594

VL - 10

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 2

M1 - e0111532

ER -